| NASDAQ (usa) |
 |
6715.56 | -12.11 | -0.18% |
| FTSE 100 (london) |
|
7487.96 | -5.12 | -0.07% |
| DAX (german) |
 |
13465.51 | 235.94 | 1.78% |
| NIKKEI 225 (japan) |
|
22420.08 | 408.47 | 1.86% |
| Hang - Seng (hong kong) |
|
28594.06 | 348.52 | 1.23% |
| NIFTY - 50 (india) | ||||
| Straits Times (singapore) |
|
3391.61 | 17.53 | 0.52% |
| KOSPI (korea) |
|
2556.47 | 33.04 | 1.31% |
| All Ordinaries (australia) |
|
6005.30 | 28.90 | 0.48% |
| BOVESPA (brazil) |
|
74092.76 | -215.73 | -0.29% |
Innate Pharma S.A (NASDAQ: IPHA)
IPHA Technical Analysis
1.5
| As on 9th Jun 2023 IPHA SHARE Price closed @ 3.23 and we RECOMMEND Buy for LONG-TERM with Stoploss of 3.01 & Sell for SHORT-TERM with Stoploss of 4.00 we also expect STOCK to react on Following IMPORTANT LEVELS. |
IPHASHARE Price
| Open | 3.30 | Change | Price | % |
| High | 3.44 | 1 Day | -0.09 | -2.71 |
| Low | 3.23 | 1 Week | 0.29 | 9.86 |
| Close | 3.23 | 1 Month | 0.41 | 14.54 |
| Volume | 30900 | 1 Year | -1.79 | -35.66 |
| 52 Week High 5.17 | 52 Week Low 1.90 | ||||
NASDAQ USA Most Active Stocks
| TSLA | 244.40 | 4.06% |
| TTOO | 0.07 | -12.50% |
| SOFI | 8.18 | 0.74% |
| FFIE | 0.33 | 6.45% |
| PONO | 1.72 | 2.38% |
| AMD | 124.92 | 3.20% |
| IDEX | 0.06 | 0.00% |
| NKLA | 0.70 | 14.75% |
| AMZN | 123.43 | -0.66% |
| AAPL | 180.96 | 0.22% |
NASDAQ USA Top Gainers Stocks
NASDAQ USA Top Losers Stocks
| IPHA Daily Charts |
IPHA Intraday Charts |
Whats New @ Bazaartrend |
IPHA Free Analysis |
|
|
IPHA Important Levels Intraday
| RESISTANCE | 3.63 |
| RESISTANCE | 3.50 |
| RESISTANCE | 3.42 |
| RESISTANCE | 3.34 |
| SUPPORT | 3.12 |
| SUPPORT | 3.04 |
| SUPPORT | 2.96 |
| SUPPORT | 2.83 |
IPHA Forecast April 2024
| 4th UP Forecast | 5.74 |
| 3rd UP Forecast | 4.93 |
| 2nd UP Forecast | 4.44 |
| 1st UP Forecast | 3.94 |
| 1st DOWN Forecast | 2.52 |
| 2nd DOWN Forecast | 2.02 |
| 3rd DOWN Forecast | 1.53 |
| 4th DOWN Forecast | 0.72 |
IPHA Weekly Forecast
| 4th UP Forecast | 5.00 |
| 3rd UP Forecast | 4.43 |
| 2nd UP Forecast | 4.08 |
| 1st UP Forecast | 3.73 |
| 1st DOWN Forecast | 2.73 |
| 2nd DOWN Forecast | 2.38 |
| 3rd DOWN Forecast | 2.03 |
| 4th DOWN Forecast | 1.46 |
IPHA Forecast2024
| 4th UP Forecast | 9.86 |
| 3rd UP Forecast | 7.73 |
| 2nd UP Forecast | 6.42 |
| 1st UP Forecast | 5.1 |
| 1st DOWN Forecast | 1.36 |
| 2nd DOWN Forecast | 0.04 |
| 3rd DOWN Forecast | -1.27 |
| 4th DOWN Forecast | -3.4 |
Innate Pharma S.A ( NASDAQ USA Symbol : IPHA )
Sector : Healthcare And Other Stocks in Same Sector
Sector : Healthcare And Other Stocks in Same Sector
IPHA Business Profile
Innate Pharma S.A., a biotechnology company, discovers, develops, and commercializes therapeutic antibodies for the treatment of oncology indications in France and internationally. The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma, as well as in Phase II clinical trials to treat refractory sézary syndrome; Monalizumab, an immune checkpoint inhibitor that is in Phase II clinical trial to treat advanced solid tumors comprising colorectal and lung cancer, as well as head and neck cancer; Avdoralimab (IPH5401), a monoclonal antibody blocking C5a binding to C5aR1 that is in Phase II clinicals trials for the treatment of COVID-19, bullous pemphigoid, chronic spontaneous urticaria, and other inflammatory diseases; and IPH5201, a blocking antibody that is in Phase 1 clinical trials targeting the CD39 immunosuppressive pathway. Its products in preclinical trials include IPH5301, an anti-CD73 antibody targeting the immunosuppressive adenosine pathway to promote antitumor immunity; IPH61, NKp46-based NK cell engager for the generation and evaluation of up to two bispecific NK cell engagers; IPH43, an anti-MICA/B antibody drug conjugate; Lumoxiti (moxetumomab pasudotox-tdfk), a tumor antigen targeting solution for the treatment of hairy cell leukemia; Anti-Siglec-9, an antibody program; IPH25, a checkpoint inhibitor; and IPH62, an NKp46-NKCE platform. Innate Pharma S.A. has licensing and collaboration agreements with AstraZeneca, Novo Nordisk A/S, Sanofi, and Orega Biotech; and co-development and license agreement with MedImmune Limited. The company was incorporated in 1999 and is headquartered in Marseille, France. Address: 117, Avenue de Luminy, Marseille, France, 13009
© 2005-2023 BazaarTrend.com All rights reserved.
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service